Next Article in Journal
Magnetic-Based Enrichment of Rare Cells from High Concentrated Blood Samples
Next Article in Special Issue
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
Previous Article in Journal
Correction: Mishra, et al.; Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. Cancers 2019, 11, 750
Previous Article in Special Issue
Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
Review

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma

1
Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan
2
Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan
3
Department of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8603, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 924; https://doi.org/10.3390/cancers12040924
Received: 8 March 2020 / Revised: 3 April 2020 / Accepted: 7 April 2020 / Published: 10 April 2020
(This article belongs to the Special Issue The Asymptomatic Version of Myeloma: MGUS and Smoldering Myeloma)
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1+ patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM. View Full-Text
Keywords: PD-L1 (B7-H1); PD-1; multiple myeloma; monoclonal gammopathy of undetermined significance (MGUS); immune checkpoint inhibitors; AKT pathway PD-L1 (B7-H1); PD-1; multiple myeloma; monoclonal gammopathy of undetermined significance (MGUS); immune checkpoint inhibitors; AKT pathway
Show Figures

Figure 1

MDPI and ACS Style

Tamura, H.; Ishibashi, M.; Sunakawa-Kii, M.; Inokuchi, K. PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers 2020, 12, 924. https://doi.org/10.3390/cancers12040924

AMA Style

Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers. 2020; 12(4):924. https://doi.org/10.3390/cancers12040924

Chicago/Turabian Style

Tamura, Hideto, Mariko Ishibashi, Mika Sunakawa-Kii, and Koiti Inokuchi. 2020. "PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma" Cancers 12, no. 4: 924. https://doi.org/10.3390/cancers12040924

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop